trial

Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia

NCTId NCT00265551
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 300
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
300
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2006-01
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
SCA-136 (200 mg)SCA-136 (400 mg)Olanzapine

Sponsors

Wyeth is now a wholly owned subsidiary of PfizerLead Sponsor

Sites

0 total

Facts & assertions

3 sourced
Enrollment
300
Phase
PHASE2
Status
COMPLETED
relationships
The graph out of here
drug
SCA-136 (200 mg)
drug
SCA-136 (400 mg)
drug
Olanzapine
drug
lead_sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
company
indication
Schizophrenia
indication
Schizophrenia
indication